Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 227

Sort by

Sort Order Select

Journal Articles

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Blood (2024) 144 (20): 2121–2135.

https://doi.org/10.1182/blood.2024024590

Published: 2024

Includes: Supplemental data

Journal Articles

Tracking Bone Marrow Regeneration after CAR-T Cell Therapy in Myeloma at Spatial Single-Cell Resolution Reveals Determinants of Prolonged Cytopenia

Jennifer Wing Lam Cheung, Prachurjya Panda, Xiang Zhou, Katrin Sinning, Ankit Agrawal, Andy Shing Fung Chan, Johannes Duell, Johannes Waldschmidt, Hermann Einsele, Martin Väth, Andreas Rosenwald, Dominic Grün, Leo Rasche

Blood (2024) 144 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2024-203052

Published: 2024

Journal Articles

Richter Syndrome-Associated Genetic Lesions in TP53 and the Cell Cycle Inhibitors CDKN2A and CDKN2B Induce Transformation of a CD5+ B Cell Subset Characterized By a Restricted IGHV Repertoire, Autoreactivity and BCR Dependence

Claudio Martines, Supriya Chakraborty, Giulia Felician, Karin Hofmann, Sasha Blasutig, Ivan Negara, Alice Bonato, Marija Vujovikj, Alberto Zamò, Andreas Rosenwald, Aleksandar J Dimovski, Dimitar G Efremov

Blood (2024) 144 (Supplement 1): 759.

https://doi.org/10.1182/blood-2024-207095

Published: 2024

Journal Articles

An Llmpp Study: Genomic Characterization of Novel PTCL- Biological Subtypes Reveal Distinctive Therapeutic Vulnerabilities

Blood (2024) 144 (Supplement 1): 456.

https://doi.org/10.1182/blood-2024-209396

Published: 2024

Journal Articles

Maintenance of CD19 Expression after Tafasitamab Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) from Clinical Trial and Real-World Settings

Johannes Duell, Diana Alvarez Arias, Hilka Rauert-Wunderlich, Florian Eisele, Alla Volgina, Beth Rumberger, Thomas Stauffer Larsen, Andreas Rosenwald

Blood (2024) 144 (Supplement 1): 2991.

https://doi.org/10.1182/blood-2024-199176

Published: 2024

Journal Articles

HIV-Associated Diffuse Large B-Cell Lymphoma Shows Different Genomic Patterns between EBV-Positive and EBV-Negative Tumors

Blood (2024) 144 (Supplement 1): 2976.

https://doi.org/10.1182/blood-2024-206279

Published: 2024

Journal Articles

Dissecting Diffuse Large B Cell Lymphoma Heterogeneity: New Insights from a State-Specific Molecular Characterization

Blood (2024) 144 (Supplement 1): 2975.

https://doi.org/10.1182/blood-2024-204797

Published: 2024

Journal Articles

The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

Andrew L. Feldman, Guangzhen Hu, Surendra Dasari, Lisa M. Rimsza, David W. Scott, Jimena B. Gimenez, Farah M. Salama, Min Shi, Elías Campo, Wing Chung Chan, James R. Cook, Giorgio Inghirami, Elaine S. Jaffe, Ryan Morin, Phillipp W. Raess, Andreas Rosenwald, Kerry J. Savage, Louis M. Staudt, George W. Wright, Catalina Amador, Jan Delabie, Timothy C. Greiner, Javeed Iqbal, Laura K. Hilton, Sarah L. Ondrejka, German Ott, Stefania Pittaluga, Graham W. Slack, Susan L. Slager, Joo Y. Song, Hao-Wei Wang, Ahmed A. Aljudi, Stephen M. Ansell, Carlos Barrionuevo, James R. Cerhan, Jennifer R. Chapman-Fredricks, Weina Chen, Laurence de Leval, Alejandro A. Gru, David L. Jaye, Liuyan Jiang, Brad S. Kahl, Kennosuke Karube, Young Hyeh Ko, Eric Mou, Matthew J. Maurer, L. Jeffrey Medeiros, Roberto N. Miranda, Naoki Oishi, Perry M. Anamarija, Akira Satou, Xueju Wang, Ryan A. Wilcox, Xiaojun Wu, Tadashi Yoshino, Yu Zeng

Blood (2024) 144 (Supplement 1): 2974.

https://doi.org/10.1182/blood-2024-202410

Published: 2024

Journal Articles

Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement- an L.L.M.P.P. Study

Blood (2024) 144 (Supplement 1): 231.

https://doi.org/10.1182/blood-2024-208880

Published: 2024

Journal Articles

Immune Cell Infiltration Impacts Chemotherapy Efficacy in B-NHL

Peter-Martin Bruch, Christina Schniederjohann, Harald Voehringer, Matthias Meyer-Bender, Sarah Koziel, Lisa-Maria Held, Erin Kim Chung, Hilka Rauert-Wunderlich, Marita Ziepert, Norbert Gattermann, Gerhard Held, German Ott, Andreas Rosenwald, Wolfgang Huber, Sascha Dietrich

Blood (2024) 144 (Supplement 1): 4383.

https://doi.org/10.1182/blood-2024-209562

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation Promotes Atherosclerosis in Mice Driven By Donor CD8+ T Cells

Haroon Shaikh, Ivana Jorgacevic, Hla Ali, Maja Bundalo, Sarah Schäfer, Michael AG Kern, Maike Büttner- Herold, Clément Cochain, Antoine-Emmanuel Saliba, Giuseppe Rizzo, Juan Vargas, Louis Boon, Wolfgang Herr, Hermann Einsele, Friederike Berberich-Siebelt, Andreas Rosenwald, Andreas Beilhack, Alma Zernecke

Blood (2024) 144 (Supplement 1): 3402.

https://doi.org/10.1182/blood-2024-194190

Published: 2024

Journal Articles

Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 4796.

https://doi.org/10.1182/blood-2024-207274

Published: 2024

Journal Articles

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Konstantinos Christofyllakis, Igor Age Kos, Bettina Altmann, Viola Poeschel, Stephanie Maurer, Vadim Lesan, Jörg-Thomas Bittenbring, Dominic Kaddu-Mulindwa, Zanir Abdi, Manfred Ahlgrimm, Sarah Altmeyer, Octavian Fleser, Gerhard Held, Maike Nickelsen, Martin Dreyling, Florian Zettl, Christian Buske, Georg Lenz, Bertram Glass, Björn Chapuy, Norbert Schmitz, German Ott, Reiner Siebert, Andreas Viardot, Florian Scherer, Roland Schmitz, Andreas Rosenwald, Dirk Hellwig, Nina Neuendorff, Theodoros Vassilakopoulos, Chrysoula Doxani, Pascal Blatt, Oguzhan Nakisli, Susanne Schmidt, Tobias Gaska, Börge Arndt, Matthias Mueller, Hanno Maximilian Witte, Martin Bentz, Volkmar Boehme, Heinz Kirchen, Markus Loeffler, Boris Kubuschock, Niklas Gebauer, Rolf Mahlberg, Julian Topaly, Alexander Bott, Kai Wille, Ralf Ulrich Trappe, Mathias J. Rummel, Gerald Illerhaus, Franziska Brunner, Martin Klump, Ulrich Kaiser, Swen Wessendorf, Iordanis Deligiannis, Bert Hildebrandt, Alexander Kiani, Thomas Illmer, Gabriele Prange-Krex, Kristina Lerch, Matthias Sandmann, Sebastian Broeckling, Uwe Martens, Bastian von Tresckow, Annkristin Heine, Holger F. Hebart, Stephan Stilgenbauer, Lorenz Thurner, Moritz Bewarder, Marita Ziepert

Blood (2024) 144 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2024-199685

Published: 2024

Journal Articles

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

Blood (2024) 144 (5): 525–540.

https://doi.org/10.1182/blood.2024024251

Published: 2024

Includes: Supplemental data

Journal Articles

Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy

Johannes Duell, Alexander M. Leipold, Silke Appenzeller, Viktoria Fuhr, Hilka Rauert-Wunderlich, Matteo Da Via, Oliver Dietrich, Christophe Toussaint, Fabian Imdahl, Florian Eisele, Nazia Afrin, Lars Grundheber, Hermann Einsele, Niels Weinhold, Andreas Rosenwald, Max S. Topp, Antoine-Emmanuel Saliba, Leo Rasche

Blood (2024) 143 (8): 685–696.

https://doi.org/10.1182/blood.2023021672

Published: 2024

Includes: Supplemental data

Journal Articles

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

Blood (2023) 142 (Supplement 1): 71.

https://doi.org/10.1182/blood-2023-178815

Published: 2023

Journal Articles

A Simplified IPI Including BCL2 Identifies IPI 3 Patients with Poor Prognosis - a GLA/ Dshnhl and Lysa Collaboration

Blood (2023) 142 (Supplement 1): 191.

https://doi.org/10.1182/blood-2023-184611

Published: 2023

Journal Articles

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Janaki Manoja Vinnakota, Francesca Biavasco, Marius Schwabenland, Chintan Chhatbar, Rachael C Adams, Daniel Erny, Sandra Duquesne, Nadia El Khawanky, Henrike Salié, Dimitrios Athanassopoulos, Lukas Braun, Dominik Schmidt, Viktor Fetsch, Rebeka N. Javorniczky, Jenny N.H.G Ho, Reinhard Marks, Ralph Wäsch, Federico Simonetta, Geoffroy Andrieux, Dietmar Pfeifer, Gianni Monaco, Christian Capitini, Terry J. Fry, Thomas Blank, Bruce R Blazar, Eva-Maria Wagner Drouet, Matthias Theobald, Clemens Sommer, Matthias Stelljes, Christian Reicherts, Astrid Jeibmann, Jens Schittenhelm, Camelia-Maria Monoranu, Andreas Rosenwald, K. Martin Kortüm, Leo Rasche, Hermann Einsele, Philipp Tobias Meyer, Joachim Brumberg, Andreas Mackensen, Michael von Bergwelt-Baildon, Roland Coras, Nathalie L. Albert, Laura M. Bartos, Matthias Brendel, Adrien Holzgreve, Melanie Boerries, Crystal L. Mackall, Justus Duyster, Natalie Koehler, Felix Strübing, Bertram Bengsch, Marco Ruella, Marion Subklewe, Louisa von Baumgarten, Saar Gill, Marco Prinz, Robert Zeiser

Blood (2023) 142 (Supplement 1): 100.

https://doi.org/10.1182/blood-2023-184867

Published: 2023

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

Journal Articles

A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

Blood (2023) 142 (Supplement 1): 6248.

https://doi.org/10.1182/blood-2023-179200

Published: 2023

NARROW

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Tracking Bone Marrow Regeneration after CAR-T Cell Therapy in Myeloma at Spatial Single-Cell Resolution Reveals Determinants of Prolonged Cytopenia

Richter Syndrome-Associated Genetic Lesions in TP53 and the Cell Cycle Inhibitors CDKN2A and CDKN2B Induce Transformation of a CD5+ B Cell Subset Characterized By a Restricted IGHV Repertoire, Autoreactivity and BCR Dependence

An Llmpp Study: Genomic Characterization of Novel PTCL- Biological Subtypes Reveal Distinctive Therapeutic Vulnerabilities

Maintenance of CD19 Expression after Tafasitamab Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) from Clinical Trial and Real-World Settings

HIV-Associated Diffuse Large B-Cell Lymphoma Shows Different Genomic Patterns between EBV-Positive and EBV-Negative Tumors

Dissecting Diffuse Large B Cell Lymphoma Heterogeneity: New Insights from a State-Specific Molecular Characterization

The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement- an L.L.M.P.P. Study

Immune Cell Infiltration Impacts Chemotherapy Efficacy in B-NHL

Allogeneic Hematopoietic Cell Transplantation Promotes Atherosclerosis in Mice Driven By Donor CD8+ T Cells

Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

A Simplified IPI Including BCL2 Identifies IPI 3 Patients with Poor Prognosis - a GLA/ Dshnhl and Lysa Collaboration

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only